ArticleAge and ageing2025
The anticholinergic medication index and dementia risk: evidence from the UK Biobank and All of Us research program.
Article in Age and ageing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnticholinergic drugs are associated with adverse effects, including cognitive decline. In this study, we externally validated the Anticholinergic Medication Index (ACMI) by investigating the association between baseline anticholinergic burden and dementia risk in two large prospective cohorts: the UK Biobank (UKB) and the US All of Us (AoU) program.
methodsWe analysed data from the UKB (n = 125 260; study period, 2000-15) and AoU (92 047; 2000-22). Cox proportional hazards models, adjusted for clinical and genetic covariates with death as a competing risk, assessed the association between baseline annual ACMI-computed anticholinergic burden and dementia risk. Exploratory genetic analyses included candidate gene analysis of acetylcholine signalling pathway genes in the UKB and development of a polygenic hazard score in AoU.
resultsPrescription of any of the 88 ACMI-listed drugs at baseline was associated with increased dementia risk (UKB HR: 1.15, 95% CI 1.09-1.21; AoU: 1.06, 1.04-1.09) and mortality (UKB: 1.23, 1.19-1.27; AoU: 1.16, 1.13-1.19). We replicated the genetic influence of APOE on dementia risk (UKB [APOE ε4 vs ε3 carriers] HR: 2.05, 1.86-2.26; AoU: 1.61, 1.44-1.80). No significant gene-drug interactions were identified.
conclusionHigher baseline ACMI scores were associated with increased risks of dementia and mortality in two large cohorts, providing external validation of the ACMI. While causal inference is not possible, these findings support the ACMI's potential utility as a prognostic tool for risk stratification and for informing future work on safer prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.